Draupnir Bio ApS: Financial statements 2018
CVR: 38546880
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -1,779,479 and a net result of DKK -2,117,554. Equity in the 2018 report amounted to DKK -1,788,946. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,779,479
- Profit/Loss
- DKK -2,117,554
- Equity
- DKK -1,788,946
- Total Assets
- DKK 4,582,267
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of October 26, 2018, Emmanuelle Coutanceau has joined the board of directors of Draupnir Bio ApS.
As of October 26, 2018, Peter Hans Andreas Seeberger has joined the board of directors of Draupnir Bio ApS.
As of October 26, 2018, Camilla Gustafsen has left the board of directors of Draupnir Bio ApS.
As of October 26, 2018, Simon Glerup Pedersen has left the board of directors of Draupnir Bio ApS.
As of October 26, 2018, Peder Søndergaard Madsen has left the board of directors of Draupnir Bio ApS.
Draupnir Bio ApS has published its interim report for the period April 4, 2017 – December 31, 2017.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The board consists of Eva-Lotta Coulter (chair), Emmanuelle Coutanceau, Ivan Burkov and Robert Andrew Donald Scott. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. According to the 2025 annual report, the company had an average of 9 employees. Equity in the 2025 report amounted to DKK 15,256,000.